Amalgamated Bank Sells 1,217 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Amalgamated Bank trimmed its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.2% during the first quarter, Holdings Channel.com reports. The fund owned 27,586 shares of the specialty pharmaceutical company’s stock after selling 1,217 shares during the quarter. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $3,425,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of JAZZ. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC increased its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $28,000. Finally, Allianz SE bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $29,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $109.45 on Friday. The stock has a market cap of $6.62 billion, a PE ratio of 14.59, a PEG ratio of 4.72 and a beta of 0.32. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The firm’s fifty day moving average price is $108.96 and its two-hundred day moving average price is $119.08.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company’s revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer directly owned 436,973 shares of the company’s stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Seamus Mulligan acquired 1,621 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the purchase, the director owned 101,621 shares of the company’s stock, valued at $10,466,963. The trade was a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 2,500 shares of company stock worth $277,930. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Robert W. Baird decreased their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Piper Sandler reissued an “overweight” rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Finally, HC Wainwright raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.